Genesis VI announces even wider line-up for December 12th 2006
The London Biotechnology Network today announced the preliminary conference programme for Genesis VI to be held again at the Queen Elizabeth II Conference Centre in Westminster on December 12th. During the morning, leading figures such as Sir Richard Sykes of Imperial College, Sir Christopher Evans of Merlin Biosciences and Dr Jeremy Haigh of Amgen will give keynote speeches on the major issues facing both the UK and international resurgent biotech sector. They will be followed by the traditional “Ones to Watch” and “Where are they now?” sessions on emerging and established London biotechs and presentation of the LBN’s Bio-Innovation Award for 2006. The afternoon however has been reshaped in response to the ever increasing number of companies and organisations wishing to participate in the highly successful event. LBN Director Tony Jones explains: “One of the major strengths of Genesis is the diversity of delegates. Whilst we know they value the general sessions, we also realise there are some specific issues they might wish to see explored. Therefore we have decided to run three afternoon parallel streams – Bio-Business, Outsourcing and Bio-Innovation – chaired by experts and small enough to generate meaningful discussion. The day will again finish with a major panel discussion and networking reception.”
Genesis VI will also in effect run over two days since in addition to a Welcome Reception at the London Stock Exchange on the evening of December 11th, delegates may also want to register for the 2nd UK Biotechnology Company Showcase on December 11th at the DTI Conference Centre. This preceding event is being jointly held with the Society for Medicines Research, providing , three streams simultaneously, two providing leading UK biotechs a chance to present their product pipelines and the third providing longer case-study scientific presentations of the discovery and development of specific NME’s. The stream topics have been chosen to reflect the UK’s traditional strengths such as oncology, anti-infectives, CNS, immunotherapies and vaccines, cardiovascular/metabolic diseases and tissue engineering.
